Literature DB >> 30363754

Transplantation for hepatocellular cancer: pushing to the limits?

Quirino Lai1, Alessandro Vitale2.   

Abstract

Milan criteria (MC) represents the cornerstone in the selection of patients with hepatocellular cancer (HCC) waiting for liver transplantation (LT). MC represent the precursor of the scores based on the idea of "utility": in other terms, the scoring systems typically used in the field of LT oncology present the exclusive aim of selecting the cases with the best post-LT outcomes. However, some other scores have been proposed specifically investigating the risk of death or tumour progression during the waiting list. In this case, the selection process is connected with the idea of "priority": patients at higher risk for drop-out (DO) should be selected, prioritising them or, conversely, deciding to de-list them due to the high risk of post-LT futile transplant. Lastly, models based on the concept of "benefit", namely the balancing between priority and utility, have been recently created. The present review aims to examine these three different types of scoring systems, trying to underline their pro and cons in the allocation process of HCC patients.

Entities:  

Keywords:  Milan criteria (MC); benefit; drop-out (DO); recurrence

Year:  2018        PMID: 30363754      PMCID: PMC6182031          DOI: 10.21037/tgh.2018.09.07

Source DB:  PubMed          Journal:  Transl Gastroenterol Hepatol        ISSN: 2415-1289


  49 in total

1.  Alpha-fetoprotein and (18)F-FDG positron emission tomography predict tumor recurrence better than Milan criteria in living donor liver transplantation.

Authors:  Geun Hong; Kyung-Suk Suh; Suk-Won Suh; Tae Yoo; Hyeyoung Kim; Min-Su Park; YoungRok Choi; Jin Chul Paeng; Nam-Joon Yi; Kwang-Woong Lee
Journal:  J Hepatol       Date:  2015-11-30       Impact factor: 25.083

2.  ABO blood group-related waiting list disparities in liver transplant candidates: effect of the MELD adoption.

Authors:  Michele Barone; Alfonso W Avolio; Alfredo Di Leo; Patrizia Burra; Antonio Francavilla
Journal:  Transplantation       Date:  2008-03-27       Impact factor: 4.939

3.  Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma.

Authors:  Karim J Halazun; Mark A Hardy; Abbas A Rana; David C Woodland; Elijah J Luyten; Suhari Mahadev; Piotr Witkowski; Abbey B Siegel; Robert S Brown; Jean C Emond
Journal:  Ann Surg       Date:  2009-07       Impact factor: 12.969

4.  Hepatocellular carcinoma patients are advantaged in the current liver transplant allocation system.

Authors:  K Washburn; E Edwards; A Harper; R Freeman
Journal:  Am J Transplant       Date:  2010-05-10       Impact factor: 8.086

Review 5.  Selection of patients with hepatocellular cancer: a difficult balancing between equity, utility, and benefit.

Authors:  Alessandro Vitale; Quirino Lai
Journal:  Transl Gastroenterol Hepatol       Date:  2017-09-21

6.  Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival.

Authors:  F Y Yao; L Ferrell; N M Bass; J J Watson; P Bacchetti; A Venook; N L Ascher; J P Roberts
Journal:  Hepatology       Date:  2001-06       Impact factor: 17.425

7.  Impact of Pretransplant Bridging Locoregional Therapy for Patients With Hepatocellular Carcinoma Within Milan Criteria Undergoing Liver Transplantation: Analysis of 3601 Patients From the US Multicenter HCC Transplant Consortium.

Authors:  Vatche G Agopian; Michael P Harlander-Locke; Richard M Ruiz; Goran B Klintmalm; Srinath Senguttuvan; Sander S Florman; Brandy Haydel; Maarouf Hoteit; Matthew H Levine; David D Lee; C Burcin Taner; Elizabeth C Verna; Karim J Halazun; Rita Abdelmessih; Amit D Tevar; Abhinav Humar; Federico Aucejo; William C Chapman; Neeta Vachharajani; Mindie H Nguyen; Marc L Melcher; Trevor L Nydam; Constance Mobley; R Mark Ghobrial; Beth Amundsen; James F Markmann; Alan N Langnas; Carol A Carney; Jennifer Berumen; Alan W Hemming; Debra L Sudan; Johnny C Hong; Joohyun Kim; Michael A Zimmerman; Abbas Rana; Michael L Kueht; Christopher M Jones; Thomas M Fishbein; Ronald W Busuttil
Journal:  Ann Surg       Date:  2017-09       Impact factor: 12.969

8.  Recurrence of hepatocellular carcinoma: importance of mRECIST response to chemoembolization and tumor size.

Authors:  D J Kim; P J Clark; J Heimbach; C Rosen; W Sanchez; K Watt; M R Charlton
Journal:  Am J Transplant       Date:  2014-05-06       Impact factor: 8.086

9.  Serum Tumor Markers Provide Refined Prognostication in Selecting Liver Transplantation Candidate for Hepatocellular Carcinoma Patients Beyond the Milan Criteria.

Authors:  Jeong-Hoon Lee; Yuri Cho; Hwi Young Kim; Eun Ju Cho; Dong Hyeon Lee; Su Jong Yu; Jae Woo Lee; Nam-Joon Yi; Kwang-Woong Lee; Seoung Hoon Kim; Jong Man Kim; Jae-Won Joh; Lewis W Teperman; James S Park; Yoon Jun Kim; Kyung-Suk Suh; Jung-Hwan Yoon
Journal:  Ann Surg       Date:  2016-05       Impact factor: 12.969

Review 10.  Hepatocellular carcinoma in patients listed for liver transplantation: Current and future allocation policy and management strategies for the individual patient.

Authors:  Joel P Wedd; Eric Nordstrom; Trevor Nydam; Janette Durham; Michael Zimmerman; Thor Johnson; W Thomas Purcell; Scott W Biggins
Journal:  Liver Transpl       Date:  2015-12       Impact factor: 5.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.